Search - tctmd.com

Displaying 1 - 19 of 19

Sort: Relevancy | Date

Andexanet Alfa Pulled From US Market

News Daily News

Andexanet Alfa Pulled From US Market

December 22, 2025

AHA Selects 2023’s Leading Cardiovascular Research

News Daily News

AHA Selects 2023’s Leading Cardiovascular Research

December 22, 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

News Conference News ESC 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

Michael O'Riordan

September 06, 2023

Early Cognitive Dysfunction After AF Ablation Doesn’t Last

News Daily News

Early Cognitive Dysfunction After AF Ablation Doesn’t Last

July 25, 2023

Andexanet Alfa, Reversal Agent for Factor Xa Inhibitors, Boosts Hemostasis

News Daily News

Andexanet Alfa, Reversal Agent for Factor Xa Inhibitors, Boosts Hemostasis

June 05, 2023

First-line Ablation Reduces AF Progression, Boosts Quality of Life

News Conference News AHA 2022

First-line Ablation Reduces AF Progression, Boosts Quality of Life

November 07, 2022

PRAGUE-17: LAA Occlusion Noninferior to DOACs Over Longer Term

News Conference News TCT 2021

PRAGUE-17: LAA Occlusion Noninferior to DOACs Over Longer Term

November 05, 2021

STROKESTOP: Small Clinical Benefit Seen With Systematic AF Screening

News Conference News EHRA 2021

STROKESTOP: Small Clinical Benefit Seen With Systematic AF Screening

April 26, 2021

VITAL RHYTHM in Print: Dose Effects of Omega-3s on AF Still Unclear

News Daily News

VITAL RHYTHM in Print: Dose Effects of Omega-3s on AF Still Unclear

March 17, 2021

First-line Ablation With Cryoballoon Gains Support From STOP AF First

News Conference News ESC 2020

First-line Ablation With Cryoballoon Gains Support From STOP AF First

September 02, 2020

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

News Features

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

October 22, 2018

CABANA Misses Primary Endpoint, but Electrophysiologists See Support for Ablation

News Conference News HRS 2018

CABANA Misses Primary Endpoint, but Electrophysiologists See Support for Ablation

May 10, 2018

Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

News Daily News

Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

May 04, 2018

Reversal Agent for Factor Xa Inhibitors Continues to Look Good: ANNEXA-4

News Conference News ACC 2018

Reversal Agent for Factor Xa Inhibitors Continues to Look Good: ANNEXA-4

March 13, 2018

News Daily News

Patients With A-fib Still Have High Mortality Risk After Appropriate Anticoagulation Is Started

December 05, 2016

News Conference News AHA 2016

Misdosing NOACs Common in Everyday Practice, With Implications for Stroke and Bleeding

November 21, 2016

News Conference News ESC 2016

Reversal Agent for Factor Xa Inhibitors Rapidly Reduces Anticoagulant Effects: ANNEXA-4

August 31, 2016

News Daily News

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

Michael O'Riordan

August 18, 2016

News Daily News

Cardiac Rehab After Acute MI Linked to Improved Survival, Medication Adherence

August 30, 2015

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.